1 Title page

- 2 Article category: Short communication
- 3 Recommended manuscript title
- 4 Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in
- 5 Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-
- 6 Blinded, Noninferiority Study
- 7

8 Authors

- 9 Masaharu Shinkai,¹ Takuhiro Sonoyama,² Akari Kamitani,² Risa Shibata,² Naomi
- 10 Seki,³ Shinya Omoto,³ Masahiro Shinoda,¹ Takashi Sato,¹ Naoki Ishii,⁴ Kenji
- 11 Igarashi,² Mari Ariyasu²
- 12
- ¹³ ¹Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
- 14 Shinagawa-ku, Tokyo 140-8522, Japan
- ¹⁵ ²Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F,
- 16 Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
- ¹⁷ ³Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome,
- 18 Toyonaka, Osaka 561-0825, Japan
- ¹⁹ ⁴Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
- 20 Shinagawa-ku, Tokyo 140-8522, Japan
- 21
- 22 Corresponding author: Mari Ariyasu
- 23 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042,
- 24 Japan
- 25 Phone: +81-6-6209-6962
- 26 Fax: +81-6-6209-8047
- 27 Email: mari.tatsuno@shionogi.co.jp
- 28
- 29 Word count: 1983/2000
- 30 References: 19/20
- 31 Abstract word count: 150/150
- 32 Tables and multipanel figures: 4/4
- 33 Supplementary material: Appendix document, 5 tables, and 2 figures

34

35 Abstract

36 In this randomized, observer-blinded, phase 2/3 study, we assessed S-268019-b-a 37 recombinant spike protein vaccine. We analyzed the noninferiority of S-268019-b 38 (n=103), versus tozinameran (n=103), when given as a booster ≥ 6 months after the 39 2-dose tozinameran regimen in Japanese adults without prior COVID-19 infection. 40 Interim results showed that S-268019-b was noninferior to tozinameran in co-primary 41 endpoints: geometric mean titer (GMT) (126.42 versus 108.20; adjusted-GMT ratio 42 [95% CI], 1.17 [0.96-1.42]; noninferiority P-value, <0.0001) and seroresponse rate 43 (both 100%; noninferiority P-value, 0.0004) for neutralizing antibodies on day 29. 44 Both vaccines elicited anti-spike protein immunoglobulin G antibodies, and produced 45 T-cell response (n=30/group) and neutralized Delta and Omicron pseudovirus 46 variants (n=24/group) in subgroups. Most participants reported low-grade 47 reactogenicity on days 1 and 2, the most frequent being fatigue, fever, myalgia, and 48 injection-site pain. No serious adverse events were reported. S-268019-b safety and 49 robust immunogenicity as a booster, supporting its use as COVID-19 booster 50 vaccine.

51

52 Keywords: booster, clinical trial, neutralization test, SARS-CoV-2, recombinant

- 53 spike protein, immunization
- 54

55 **JRCT ID**: jRCT2031210470

56 Highlights

- 57 Third COVID-19 vaccine dose (booster) enhances immune response • 58 Interim phase 2/3 data for booster ≥6 months after the 2nd dose in Japan are • 59 shown S-268019-b and tozinameran were safe and equal in inducing neutralizing 60 ٠ antibodies 61 Both boosters neutralized Delta and Omicron pseudovirus and induced T-cell 62 ٠ 63 response
- Results support use of S-268019-b as a booster in vaccinated adults

65 Introduction

66 Cases of coronavirus disease 2019 (COVID-19) caused by severe acute 67 respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasing periodically 68 because of several reasons. A third vaccine dose (booster) is recommended 69 because of concerns regarding waning humoral immunity over 6 months after the 70 second dose [1] and consequent reduced effectiveness against SARS-CoV-2 71 infection [2], as well as threats from new mutant strains that may escape the 72 vaccine-mediated immunity. Booster immunization can substantially improve the 73 humoral immune response against the emerging variants, including Omicron [3], [4].

74 Shionogi & Co., Ltd., has developed a novel vaccine candidate—S-268019-75 b-comprising a modified recombinant spike protein of SARS-CoV-2 (S-910823, 76 antigen) produced using the baculovirus expression system in insect cells and a 77 squalene-based adjuvant (A-910823). In a double-blinded, phase 1/2 trial, S-268019-78 b showed tolerability and a robust immunogenic response 4 weeks after the second 79 dose [5, Unpublished results]. Here, we present the interim results of a phase 2/3, 80 randomized trial, wherein the immunogenicity and safety of a single booster dose of 81 S-268019-b or tozinameran were assessed in Japan.

82

83 Methods

84 Study design and participants

This phase 2/3, single-center, randomized, observer-blinded, activecontrolled, noninferiority trial comprised three periods: screening (day -28 to -1), evaluation (day 1 to 29), and follow-up (day 30 to 365) (**Figure 1**).

Participants were healthy immunocompetent Japanese adults (aged ≥20 years) who had received two doses of tozinameran (BNT162b2; *Pfizer/BioNTech* mRNA vaccine), with the second dose received ≥6 months ago. Individuals with laboratoryconfirmed SARS-CoV-2 infection at screening or known history of SARS-CoV-2 infection were excluded (See **Supplementary Methods** for details).

Eligible participants were randomized 1:1, stratified by age (<40 and ≥40
years) and sex, to receive an intramuscular injection of either 0.5 mL of S-268019-b
(10 µg antigen prepared with 50% v/v oil-in-water adjuvant emulsion) or 0.3 mL of
tozinameran (30 µg in saline) on day 1.

The study (jRCT2031210470) was conducted in compliance with the protocol, the Declaration of Helsinki and Council for International Organizations of Medical

99 Sciences International Ethical Guidelines. the International Council for 100 Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good 101 Clinical Practice Guidelines, other applicable laws and regulations, and was 102 approved by Institutional Review Board of Tokyo Shinagawa Hospital Medical 103 Corporation Association Tokyokyojuno-kai. All participants gave their written 104 informed consent.

105

106 Outcomes

107 The primary objective of the study was to assess the noninferiority of 108 S-268019-b versus tozinameran as a booster dose in inducing SARS-CoV-2 109 neutralizing antibodies on day 29. The co-primary endpoints included day 29 110 geometric mean titer (GMT) and seroresponse rate (SRR) for SARS-CoV-2 111 neutralizing antibodies. SRR was defined as the proportion of participants with a 112 post-vaccination antibody titer \geq 4-fold higher than the baseline.

113 Secondary endpoints comprised other immunogenicity parameters and safety. 114 These included GMT, geometric mean fold rise (GMFR), and SRR for neutralizing 115 antibodies and anti-spike protein immunoglobulin G (IgG) antibodies on days 15 and 116 29. Exploratory analyses in a smaller sample included geometric means of 50% 117 neutralization titer (NT_{50}) against SARS-CoV-2 pseudovirus strains (wildtype 118 [D614G], Delta, and Omicron) on day 29 and T-cell response on day 15. Safety 119 endpoints included incidence of adverse events (AEs), serious AEs, AEs of special 120 interest, treatment-related AEs (TRAEs), medically attended TRAEs, solicited 121 TRAEs, and changes in laboratory test values. Immunogenicity variables with titer 122 values below the lower limit of quantification (LLOQ) were replaced with 0.5 x LLOQ.

123

124 Statistical analyses

125 The study used a noninferiority design. Noninferiority of S-268019-b to 126 tozinameran is confirmed when the lower limit of 95% CI is >0.67 for GMT ratio 127 (S-268019-b/tozinameran) derived from the analysis of covariate model with age and 128 sex as covariates, and more than -10% for SRR difference (S-268019-b minus 129 tozinameran) by the Farrington-Manning method for neutralizing antibodies on day 130 29 [6]. The immunogenicity subset included participants who received ≥ 1 dose of the 131 study intervention, had ≥1 post-vaccination immunogenicity data, and were negative 132 for anti-SARS-CoV-2 N-protein antibody at screening. The safety analysis subset

included participants who received ≥ 1 dose of the study intervention. All analyses were conducted based on the actual intervention administered.

Data were summarized using measures of central tendency, dispersion, and frequency distribution. Unless otherwise noted, all statistical tests were performed at the two-sided α =0.05. Missing values were not imputed. All analyses were performed using SAS[®] v9.4 (SAS Institute, NC, USA). (See **Supplementary Appendix** for detailed methods and statistical analyses).

140

141 **Results**

142 Trial Participants

All 206 participants screened were enrolled in the study (S-268019-b, n=103; tozinameran, n=103) during December 3–22, 2021 (**Supplementary Figure 1**). Baseline demographics and participant characteristics were balanced across S-268019-b and tozinameran groups: median age (range) was 30.0 (21-59) and 31.5 (21-60) years; male population, 70% and 72%, respectively (**Supplementary Table** 148 **1**).

149

150 Immunogenicity

151 Per day 29 analysis, both co-primary endpoints were met: as a booster, 152 S-268019-b was noninferior to tozinameran in SARS-CoV-2 neutralization. GMTs 153 (95% CIs) for neutralizing antibodies at baseline were 5.53 (4.87-6.28) for S-154 268019-b group and 6.70 (5.76-7.78) for tozinameran, which increased to 126.42 155 (109.76-145.62) and 108.20 (94.57-123.80), respectively, by day 29 (adjusted-156 GMTR 1.17; 95% CI 0.96-1.42; one-sided P-value for noninferiority, <0.0001). The 157 SRR was 100% for both groups (SRR difference 0.0; 95% CI –5.8 to 5.8; one-sided 158 *P-value* for noninferiority, 0.0004) (Figure 2A and Table 1). The GMTs (95% CIs) for 159 anti-spike protein IgG antibodies at baseline were 1475.9 (1280.1-1701.6) for S-160 268019-b and 1795.9 (1536.9-2098.6) for tozinameran; these were elevated to 161 48844.0 (41855.3-56999.7) and 55214.8 (49013.5-62200.7), respectively, on day 29 162 (Figure 2B), with both groups showing 100% SRR (Supplementary Table 2). The 163 GMFR and GMT results were consistent (Supplementary Table 2 and Figure 2). 164 Furthermore, the geometric mean NT_{50} against SARS-CoV-2 pseudovirus

variants on day 29 were assessed in a smaller sample of the immunogenicity subset

166 (n=24/group). The sampling ensured no significant differences in age and 167 neutralizing antibody titer against live wildtype virus on day 29 compared with the 168 entire cohort (**Supplementary Table 3**). Serum samples from both vaccine groups 169 neutralized Delta and Omicron pseudovirus variants with similar potency, as 170 indicated by NT_{50} values relative to tozinameran (**Figure 2C**). T-cell responses were 171 assessed for a subgroup (n=30/group) sampled from participants who gave consent 172 for cellular immunity assessments. Both vaccines induced antigen-specific 173 polyfunctional CD4⁺ T-cell responses, as reflected in the interferon-gamma and 174 interleukin-2 expression on day 15 (Supplementary Figure 2). A strong bias toward 175 the T-helper type 1 phenotype was noted.

- 176
- 177 Safety

178 Both, S-268019-b and tozinameran, displayed an acceptable safety profile as 179 a booster. There were no treatment-emergent serious AEs, deaths, grade 4-5 180 solicited TRAEs, or AEs of special interest reported until data cutoff date (February 181 4, 2022) (Supplementary Table 4). Overall, 96.1% (99/103) participants reported 182 375 TRAEs in the S-268019-b group, and 98.1% (101/103) participants reported 464 183 TRAEs in the tozinameran group. Furthermore, solicited systemic TRAEs were 184 reported by 69.9% (72/103) and 78.6% (81/103) participants and solicited local 185 TRAEs by 68.0% (70/103) and 72.8% (75/103) participants in the S-268019-b and 186 tozinameran groups, respectively. The most frequently reported solicited TRAEs 187 within 7 days in both booster groups were injection-site pain, fatigue, fever, myalgia, 188 and headache (Table 2). Most of the solicited TRAEs were grade 1-2 and were 189 reported on day 1-2 of the booster dose injection (Supplementary Table 5). One 190 participant in the S-268019-b group and four participants in the tozinameran group 191 experienced grade 3 solicited TRAEs.

192

193 Discussion

This study showed that S-268019-b as a booster (third) dose was noninferior to tozinameran in inducing SARS-CoV-2 neutralizing antibodies. Both vaccines induced neutralizing antibodies against pseudovirus variants, and also elicited antispike protein IgG antibodies and T-cell responses within a month after the booster dose.

199 In other booster-dose studies, a third dose of either homologous or 200 heterologous vaccines administered 3-9 months after the initial vaccination elicited 201 robust immunogenicity against SARS-CoV-2 variants [7], [8], [9], [10], [11], [12]. In 202 the COV-BOOST trial, immunogenicity of various types of vaccines given as the third 203 dose was assessed in participants with primary vaccination with either tozinameran 204 or AZD-1222 [12]. While the booster dose of all types of vaccines (mRNA, protein 205 subunit, adenovirus vector, and inactivated virus) amplified immune responses, 206 mRNA vaccines (tozinameran and mRNA-1273) induced more potent 207 immunogenicity than other types of vaccines [12]. Considering that S-268019-b 208 booster is as immunogenic as the tozinameran booster, S-268019-b may elicit more 209 potent humoral immunogenicity than other types of vaccines in the COV-BOOST 210 study, although a direct comparison is not possible.

211 Although no correlates of protection have been established in COVID-19, the 212 neutralizing antibody titer against SARS-CoV-2 after primary vaccination is highly 213 correlated with clinical efficacy against symptomatic COVID-19 [13]. Humoral 214 immunity in COVID-19 is known to wane over time, especially after 6 months [1], and 215 so does protection against symptomatic COVID-19 [2]. In this study, lower baseline 216 titers for neutralizing antibodies ≥6 months after the 2-dose tozinameran vaccination 217 were observed, consistent with previous reports. Meanwhile, studies have reported 218 that a booster dose of tozinameran after 2 doses of tozinameran enhances humoral 219 immunity [7], [12]. Moreover, a report from Israel stated greater efficacy against 220 COVID-19-related hospitalization and death after three versus two tozinameran 221 doses [14]. Since our results show noninferiority of S-268019-b to tozinameran in 222 inducing neutralizing antibodies, it is speculated that S-28019-b may also show 223 clinical efficacy similar to the booster tozinameran, although further investigations to 224 support this theory are warranted.

A previous study showed that the NT_{50} against the live Omicron virus after two doses of tozinameran was below the detection limit and 61-fold lower compared with the wildtype NT_{50} [15]. However, the third (booster) dose of tozinameran elicited neutralizing antibody titer against Omicron, with NT_{50} only 6-fold lower than that with the wildtype [15]. Moreover, the tozinameran booster dose protected against symptomatic COVID-19 due to Omicron [16]. The current findings showing that S-268019-b and tozinameran are similar with respect to neutralizing antibody levels

against Omicron suggest that S-28019-b might also show similar clinical efficacyagainst symptomatic COVID-19 due to Omicron.

234 The T-cell response in COVID-19 is crucial for sustained protection from 235 severe disease progression [17], [18]. Additionally, the T-cell response elicited by 236 COVID-19 infection or prior vaccination is considered cross-reactive against other 237 variants, including Omicron [19]. In the current study, we only examined the T-cell 238 response to the original wildtype strain, in which S-268019-b showed a response 239 similar to tozinameran. However, due to the cross-reactive nature of the T-cell 240 response, it is speculated that the T-cell response elicited by S-268019-b may 241 possibly be effective in preventing severe diseases caused by Omicron and other 242 future variants.

243 In this study, both vaccines led to mainly low-grade reactogenicity, with fever, 244 fatigue, myalgia, and injection-site pain being commonly reported, usually within 2 245 days of the booster dose. Compared with tozinameran, S-268019-b led to a lower 246 incidence of solicited TRAEs. Similarly, across all 7 booster vaccines in the 247 COV-BOOST trial, the most frequently solicited AEs reported within 7 days were low-248 grade fatigue, headache, and local pain [12]. Despite the differences in population 249 and methodologies across different studies, reactogenicity patterns seem largely 250 consistent across studies after the booster dose of either an mRNA [7], [8], 251 adenovirus vector [9], or protein subunit vaccine [10], [11], [12].

252 This is the first clinical trial report of a recombinant spike protein vaccine 253 showing its noninferiority to an mRNA vaccine as a booster dose in Japanese 254 participants. Some limitations of this study must however be acknowledged. The 255 study (1) was designed for an immunocompetent adult Japanese cohort with no 256 known history of SARS-CoV-2 infection and prior vaccination with only tozinameran, 257 and (2) has a short follow-up duration for interim analysis and relatively small sample 258 size. Also, this study was not powered to demonstrate clinical efficacy. Despite these 259 limitations, a booster dose of the recombinant spike protein vaccine, S-268019-b, 260 elicited robust immunogenicity against SARS-CoV-2, with mostly low-grade 261 reactogenicity.

262

263 Conclusion

The booster dose of S-268019-b vaccine was noninferior to tozinameran booster as per the findings of GMT and SRR for SARS-CoV-2 neutralizing

antibodies, and was well-tolerated in fully vaccinated adult Japanese participants.
S-268019-b booster was comparable with tozinameran booster in neutralizing the
pseudovirus variants, Delta and Omicron. Thus, S-268019-b might be a future option
for COVID-19 booster vaccine in adults.

270

Funding: This work was supported by Shionogi & Co., Ltd., and Ministry of Health, Labour and Welfare (MHLW) under its supplementary budget for emergency maintenance associated with the vaccine production system. Preparation of clinical trial materials of S-268019-b was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP21nf010626.

276

277 Acknowledgments: The authors thank Ms. Kiyomi Kabasawa, Ms Wakana Abe, Ms 278 Harue Otsuka, Ms. Emi Kawabe, Ms. Narumi lida, and Ms Etsuko Tanaka for 279 supporting clinical trials as clinical research coordinator, and Dr. Kenichi Kamachi 280 and all the staff of Tokyo Shinagawa Hospital for supporting the clinical trials, and 281 Ms. Haruna Hayashi and Mr. Satoshi Kojima (Shionogi & Co., Ltd.) for supporting 282 manuscript development. The authors also thank Dr. Minal Jaggar, PhD, Dr. Vidula 283 Bhole, MD, MHSc, and Mr. Ivan D'Souza, MS, of MedPro Clinical Research for 284 providing medical writing support for this manuscript, which was funded by Shionogi 285 & Co., Ltd.

286

287 Disclosures/potential conflicts of interests

- 288 M. Shinkai, M. Shinoda, T. Sato, and N. Ishii have no conflicts of interest to declare.
- 289 TS, AK, RS, NS, SO, KI, and MA are employees of Shionogi & Co., Ltd.

290 References

| 291 | [1] | Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning |
|-----|------|---------------------------------------------------------------------------------|
| 292 | | immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N |
| 293 | | Engl J Med 2021;385:e84. https://doi.org/10.1056/nejmoa2114583 |
| 294 | [2] | Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et |
| 295 | | al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a |
| 296 | | large integrated health system in the USA: a retrospective cohort study. |
| 297 | | Lancet (London, England) 2021;398:1407–16. https://doi.org/10.1016/S0140- |
| 298 | | 6736(21)02183-8 |
| 299 | [3] | Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan |
| 300 | | ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing |
| 301 | | immunity against SARS-CoV-2 Omicron variant. Cell 2022;185:457–66. |
| 302 | | https://doi.org/10.1016/J.CELL.2021.12.033 |
| 303 | [4] | Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et |
| 304 | | al. mRNA booster immunization elicits potent neutralizing serum activity |
| 305 | | against the SARS-CoV-2 Omicron variant. Nat Med 2022:1–4. |
| 306 | | https://doi.org/10.1038/s41591-021-01676-0 |
| 307 | [5] | Iwata S, Sonoyama I, Kamitani A, Shibata R, Homma I, Omoto S, et al. |
| 308 | | Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: a report |
| 309 | | of interim findings. [Vaccine: Submitted]. |
| 310 | [6] | Office of Vaccines and Blood Products, Pharmaceuticals and Medical Device |
| 311 | | Agency, Japan. Principles for the evaluation of vaccines against the novel |
| 312 | | coronavirus SARS-CoV-2 (Appendix 3). |
| 313 | | https://www.pmda.go.jp/files/000243339.pdf; 2021 [accessed 25 February |
| 314 | | 2022]. |
| 315 | [7] | Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. |
| 316 | | SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med |
| 317 | | 2021;385:1627–9. https://doi.org/10.1056/NEJMc2113468 |
| 318 | [8] | Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity |
| 319 | | of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim |
| 320 | | analysis. Nat Med 2021;27:2025–31. https://doi.org/10.1038/s41591-021- |
| 321 | | 01527-у |
| 322 | [9] | Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. |
| 323 | | Reactogenicity and immunogenicity after a late second dose or a third dose of |
| 324 | | ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials |
| 325 | | (COV001 and COV002). Lancet 2021;398:981–90. |
| 326 | | https://doi.org/10.1016/S0140-6736(21)01699-8 |
| 327 | [10] | Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. |
| 328 | | Immunogenicity and safety following a homologous booster dose of a SARS- |
| 329 | | CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 |
| 330 | | randomized placebo-controlled trial. MedRxiv 2021:2021.12.23.21267374. |
| 331 | | https://doi.org/10.1101/2021.12.23.21267374 |
| 332 | [11] | Cao Y, Hao X, Wang X, Wu Q, Song R, Zhao D, et al. Humoral |
| 333 | | immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two |

| 334 335 | | doses of inactivated vaccine. Cell Res 2021321 2021;32:107–9. https://doi.org/10.1038/s41422-021-00596-5 |
|------------|------|-------------------------------------------------------------------------------------------------------------|
| 336 | [12] | Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. |
| 337 | | Safety and immunogenicity of seven COVID-19 vaccines as a third dose |
| 338 | | (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK |
| 339 | | (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. |
| 340 | | Lancet 2021;398:2258-76. https://doi.org/https://doi.org/10.1016/S0140- |
| 341 | | 6736(21)02717-3 |
| 342 | [13] | Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. |
| 343 | | Neutralising antibody titres as predictors of protection against SARS-CoV-2 |
| 344 | | variants and the impact of boosting: a meta-analysis. The Lancet Microbe |
| 345 | | 2022;3:e52-61. https://doi.org/10.1016/S2666-5247(21)00267-6 |
| 346 | [14] | Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. |
| 347 | | Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for |
| 348 | | preventing severe outcomes in Israel: an observational study. Lancet |
| 349 | | (London, England) 2021;398:2093–100. https://doi.org/10.1016/S0140- |
| 350 | | 6736(21)02249-2 |
| 351 | [15] | Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. |
| 352 | | Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited |
| 353 | | human sera. Science 2022;375:678–80. |
| 354 | | https://doi.org/10.1126/science.abn7591 |
| 355 | [16] | Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. |
| 356 | | Association between 3 doses of mRNA COVID-19 vaccine and symptomatic |
| 357 | | infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. |
| 358 | | 2022;327(7):639-51. https://doi:10.1001/jama.2022.0470 |
| 359 | [17] | Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell |
| 360 | | and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term |
| 361 | | immune responses in COVID-19 convalescent individuals. Sci Transl Med |
| 362 | | 2021;13:7517. https://doi.org/10.1126/scitranslmed.abf7517 |
| 363 | [18] | Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol |
| 364 | | 2022;23:186–93. https://doi.org/10.1038/s41590-021-01122-w |
| 365 | [19] | Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, et al. Ancestral |
| 366 | | SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med |
| 367 | | 2022:1–5. https://doi.org/10.1038/s41591-022-01700-x |

| 368 | Figure legends | | | | | |
|-----|--------------------------------------------------------------------------------------------------|--|--|--|--|--|
| 369 | Figure 1: Study design, vaccine regimen, and key assessments | | | | | |
| 370 | | | | | | |
| 371 | NT ₅₀ , 50% neutralization titer. | | | | | |
| 372 | | | | | | |
| 373 | Figure 2: GMTs in the tozinameran and S-268019-b groups for (A) neutralizing | | | | | |
| 374 | antibodies against live wildtype virus by cytopathic effect, (B) anti-spike protein IgG, | | | | | |
| 375 | and (C) relative NT_{50} against pseudotyped virus variants | | | | | |
| 376 | | | | | | |
| 377 | GMT, geometric mean titer; IgG, immunoglobulin G; LLOQ, lower limit of | | | | | |
| 378 | quantification; NT_{50} , 50% neutralization titer. | | | | | |
| 379 | Data are presented as GMTs and 95% Cls. In Figure 2C, white and grey circles | | | | | |
| 380 | represent individual relative NT_{50} values for the tozinameran (n=24) and S-268019-b | | | | | |
| 381 | (n=24) groups, respectively, relative to group GMT for tozinameran, on day 29. | | | | | |
| 382 | Titer values reported as below the LLOQ were replaced with 0.5 \times LLOQ. The LLOQ | | | | | |
| 383 | was 5 for neutralizing antibodies and 100 for anti-spike protein IgG. The 95% CI | | | | | |
| 384 | were constructed using Student's <i>t</i> distribution for log-transformed titers. | | | | | |
| 385 | | | | | | |
| 386 | Supplementary Figure 1: Participant flow | | | | | |
| 387 | | | | | | |
| 388 | Supplementary Figure 2: Immunologic assays from PBMCs for percent of CD4 ⁺ T | | | | | |
| 389 | cells positive for IFN- $\!\gamma$, IL-2, IL-4, and IL-5 at baseline and on day 15 in the study | | | | | |
| 390 | groups | | | | | |
| 391 | | | | | | |
| 392 | IFN, interferon; IL, interleukin; PBMCs, peripheral blood mononuclear cells. | | | | | |
| 393 | Data are presented as mean and 95% CI. Dark circles represent baseline and light | | | | | |
| 394 | squares represent day 15 values of immune marker expression for individual | | | | | |
| 395 | participants in the study groups (n=30/group). The 95% CI were constructed using | | | | | |
| | | | | | | |

396 the Clopper-Pearson method for proportion data.

397 Table 1: Co-primary endpoints (GMT and SRR) with GMTR and SRR difference in

398 SARS-CoV-2 neutralizing antibody response on day 29, and GMT and SRR at

baseline and on day 15

| Outcome | Tozir | nameran (n: | =101) | S-268019-b (n=103) | | | |
|-------------------------|-----------------------|-------------|---------|--------------------|----------|-------------|--|
| (95% CI) | Baseline ^a | Day 15 | Day 29 | Baseline | Day 15 | Day 29 | |
| | 6.70 | 138.53 | 108.20 | 5.53 | 128.14 | 126.42 | |
| GMT [♭] | (5.76, | (121.61, | (94.57, | (4.87, | (112.79, | (109.76, | |
| | 7.78) | 157.80) | 123.80) | 6.28) | 145.57) | 145.62) | |
| | | | | | | 1.17 | |
| GMTR [℃] | - | - | - | - | - | (0.96, | |
| | | | | | | 1.42) | |
| | | 99.0 | 100.0 | | 100.0 | 100.0 | |
| SRR ^d | - | (94.6, | (96.4, | - | (96.5, | (96.5, | |
| | | 100.0) | 100.0) | | 100.0) | 100.0) | |
| SRR | | | | | | 0.0 | |
| difference ^d | - | - | - | - | - | (-5.8, 5.8) | |

400 GMT, geometric mean titer; GMTR, geometric mean titer ratio; SARS-CoV-2, severe 401 acute respiratory syndrome coronavirus 2; SRR, seroresponse rate.

402 Criteria for noninferiority confirmed when lower limit of 95% Cl >0.67 for GMTR 403 (S-268019-b/tozinameran) and > -10% for SRR difference (S-268019-b - 404 tozinameran).

405 ^aAt baseline, tozinameran group had 102 participants. ^bThe GMTs with 406 corresponding 95% CIs were estimated by back transformation from the arithmetic 407 mean and the 95% CIs based on the Student's t distribution of log-transformed titers 408 to the original scale. ^cThe GMTR and its 95% CI were obtained using analysis of 409 covariance model fitted on the log-transformed titers; the model included intervention 410 group as the fixed effect as well as age (continuous) and sex as covariates. ^aThe 411 95% CI were constructed using the Clopper-Pearson method for SRR and the 412 Farrington-Manning method for SRR difference.

413 **Table 2:** Incidence of solicited local and systemic treatment-related adverse events (experienced within 7 days after the booster) by

414 severity in the study groups

| | Tozinameran (n=103) | | | | S-268019-b (n=103) | | | |
|---------------------------------------------------|---------------------|-----------|-----------|---------|--------------------|-----------|-----------|---------|
| | Any grade | Grade 1 | Grade 2 | Grade 3 | Any grade | Grade 1 | Grade 2 | Grade 3 |
| Any systemic solicited TRAEs | 81 (78.6) | 46 (44.7) | 31 (30.1) | 4 (3.9) | 72 (69.9) | 56 (54.4) | 15 (14.6) | 1 (1.0) |
| Fatigue | 55 (53.4) | 32 (31.1) | 22 (21.4) | 1 (1.0) | 45 (43.7) | 36 (35.0) | 9 (8.7) | - |
| Fever | 61 (59.2) | 52 (50.5) | 7 (6.8) | 2 (1.9) | 40 (38.8) | 37 (35.9) | 2 (1.9) | 1 (1.0) |
| Myalgia | 49 (47.6) | 42 (40.8) | 7 (6.8) | - | 42 (40.8) | 41 (39.8) | 1 (1.0) | - |
| Headache | 43 (41.7) | 31 (30.1) | 12 (11.7) | - | 26 (25.2) | 19 (18.4) | 7 (6.8) | - |
| Arthralgia | 12 (11.7) | 7 (6.8) | 5 (4.9) | - | 8 (7.8) | 6 (5.8) | 2 (1.9) | - |
| Nausea/vomiting | 5 (4.9) | 5 (4.9) | - | - | 5 (4.9) | 4 (3.9) | 1 (1.0) | - |
| Diarrhea | 6 (5.8) | 4 (3.9) | 1 (1.0) | 1 (1.0) | 4 (3.9) | 3 (2.9) | 1 (1.0) | - |
| Chills | 7 (6.8) | 3 (2.9) | 4 (3.9) | - | 4 (3.9) | 2 (1.9) | 2 (1.9) | - |
| Any local solicited TRAEs (at the injection site) | 75 (72.8) | 70 (68.0) | 5 (4.9) | - | 70 (68.0) | 68 (66.0) | 2 (1.9) | - |
| Pain | 75 (72.8) | 70 (68.0) | 5 (4.9) | - | 68 (66.0) | 68 (66.0) | - | - |
| Erythema/redness | 9 (8.7) | 9 (8.7) | - | - | 7 (6.8) | 6 (5.8) | 1 (1.0) | - |
| Swelling | 1 (1.0) | 1 (1.0) | - | - | 1 (1.0) | - | 1 (1.0) | - |

415 TRAEs, treatment-related adverse events.

416 Data are presented as number (%) of the participants. No participants reported grade 4 or 5 solicited TRAEs.

Page 15 of 15





Study day 29